Apyx Medical Corporation
APYX evidence brief
What we can confirm
- BioSniper Score:
- 4.9 / 10
- Market Cap:
- $128.9M
- Lead Asset:
- j-plasma (Approved)
What it means
What to watch
Prepared research question
What matters most for APYX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · APYX
Apyx Medical Corporation (APYX) is a surgical aesthetics company that markets Renuvion and the AYON Body Contouring System, focusing on minimally invasive skin tightening and body contouring procedures.
Key risk: Regulatory delay risk
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$128.9M
Cash Runway
—
Lead Asset
j-plasma (Approved)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates · 1 clinical trial for Apyx Medical Corporation.
Apyx Medical Corporation (APYX) is a surgical aesthetics company that markets Renuvion and the AYON Body Contouring System, focusing on minimally invasive skin tightening and body contouring procedures.
- Cash & equivalents of $27.6M as of 2026-06-30 [sec]
- Total revenue of $13.9M and net income of -$3.2M as of 2026-06-30 [sec]
- Launched Renuvion in China in July 2025 after NMPA clearance [sec · filed 2026-06-26]
- Submitted FDA 510(k) for AYON label expansion to include power liposuction, anticipating clearance in Q2 2026 [sec · filed 2026-06-26]
- New clinical data published May 2026 shows improvement in cellulite and skin laxity using Avéli and Renuvion [news · published 2026-05-21]
What works
- Revenue growth driven by AYON launch: Surgical Aesthetics revenue increased ~38% year-over-year in Q4 2025, with U.S. revenue up ~51% [news · published 2026-01-12]
- GLP-1 weight-loss drug trend is fueling demand for body contouring procedures, positioning Renuvion and AYON favorably [news · published 2026-08-12]
- Company raised ~$9.1M net proceeds from a November 2025 stock offering, strengthening its cash position [sec · filed 2026-06-26]
What to weigh
- Company has incurred recurring net losses and cash outflows from operations, and anticipates continued near-term losses [sec_mda · as of 2026-05-07]
- Net income was -$3.2M as of 2026-06-30, indicating ongoing unprofitability [sec]
- Dependence on FDA clearance for AYON label expansion (power liposuction) introduces regulatory uncertainty; clearance anticipated but not yet received [sec · filed 2026-06-26]
From the filings
Quoted directly from source documents.
FDA 510(k) submission for AYON label expansion
“we had submitted the 510(k) premarket notification to the FDA for the label expansion of AYON to include power liposuction”
SEC filings · June 26, 2026
Recurring net losses and cash outflows
“We have incurred recurring net losses and cash outflows from operations and we anticipate that losses will continue in the near term”
SEC MD&A · May 7, 2026
Risks & what to watch (3)›
Key risks
- Regulatory delay risk — FDA clearance for AYON power liposuction label expansion is pending; any delay could slow revenue growth [sec · filed 2026-06-26]
- Continued operating losses — Company reports recurring net losses and expects near-term losses to persist, pressuring cash reserves [sec_mda · as of 2026-05-07]
- Dependence on equity/debt financing — Company may need additional financing to fund operations if cash from sales is insufficient [sec_mda · as of 2026-05-07]
What to watch
- FDA decision on AYON 510(k) for power liposuction, expected in Q2 2026 [sec · filed 2026-06-26]
- Adoption of Renuvion in China following initial market clearance [sec · filed 2026-06-26]
- Impact of GLP-1 drug trend on demand for body contouring procedures [news · published 2026-08-12]
- Next quarterly financial results to assess revenue growth and loss trajectory [news · published 2026-04-23]
Sources: News · SEC filings · SEC MD&A · Generated September 30, 2026 · How we verify sources →
Run Apyx Medical Corporation through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Apyx Medical Corporation facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
D/E 4.69
Lead: Approved
2 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Financials
Short Interest
as of May 20, 2026- % of float
- 0.6%
- Days to cover
- 2.0
- Shares short
- 221,167
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
APYX short interestGovernance
Frequently asked questions
What is the AI investment thesis for Apyx Medical Corporation?
Apyx Medical Corporation (APYX) is a surgical aesthetics company that markets Renuvion and the AYON Body Contouring System, focusing on minimally invasive skin tightening and body contouring procedures.
What is Apyx Medical Corporation's lead drug candidate?
Apyx Medical Corporation's most advanced tracked candidate is j-plasma (Approved) for Cutting, coagulation and ablation of soft tissue.
Who is the CEO of Apyx Medical Corporation?
Mr. Charles D. Goodwin II is the chief executive officer of Apyx Medical Corporation (APYX).
Where is Apyx Medical Corporation headquartered?
Apyx Medical Corporation (APYX) is headquartered in Clearwater, FL, United States.
What therapeutic areas does Apyx Medical Corporation focus on?
Apyx Medical Corporation develops therapies across Oncology, Dermatology, Hematology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.